Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors

Yantao He, Li Fan Zeng, Zhi Hong Yu, Rongjun He, Sijiu Liu, Zhong-Yin Zhang

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Protein tyrosine phosphatases (PTPs) constitute a large and structurally diverse family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. Malfunction of PTP activity has significant implications in many human diseases, and the PTP protein family provides an exciting array of validated diabetes/obesity (PTP1B), oncology (SHP2), autoimmunity (Lyp), and infectious disease (mPTPB) targets. However, despite the fact that PTPs have been garnering attention as novel therapeutic targets, they remain largely an untapped resource. The main challenges facing drug developers by the PTPs are inhibitor specificity and bioavailability. Work over the last ten years has demonstrated that it is feasible to develop potent and selective inhibitors for individual members of the PTP family by tethering together small ligands that can simultaneously occupy both the active site and unique nearby peripheral binding sites. Recent results with the bicyclic salicylic acid pharmacophores indicate that the new chemistry platform may provide a potential solution to overcome the bioavailability issue that has plagued the PTP drug discovery field for many years. Structural analysis of PTP-inhibitor complexes reveals molecular determinants important for the development of more potent and selective PTP inhibitors, thus offering hope in the medicinal chemistry of a largely unexploited protein class with a wealth of attractive drug targets.

Original languageEnglish
Pages (from-to)1940-1946
Number of pages7
JournalBioorganic and Medicinal Chemistry
Volume20
Issue number6
DOIs
StatePublished - Mar 15 2012

Fingerprint

Protein Tyrosine Phosphatases
Salicylates
Biological Availability
benzofuran
indole
Phosphorylation
Proteins
Oncology
Salicylic Acid
Pharmaceutical Chemistry
Drug Discovery
Medical problems
Autoimmunity
Structural analysis
Pharmaceutical Preparations
Communicable Diseases
Tyrosine
Catalytic Domain
Obesity
Binding Sites

Keywords

  • Bioavailability
  • Combinatorial chemistry
  • Inhibitor specificity
  • Protein tyrosine phosphatases
  • Salicylic acid
  • Therapeutic target

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry

Cite this

Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. / He, Yantao; Zeng, Li Fan; Yu, Zhi Hong; He, Rongjun; Liu, Sijiu; Zhang, Zhong-Yin.

In: Bioorganic and Medicinal Chemistry, Vol. 20, No. 6, 15.03.2012, p. 1940-1946.

Research output: Contribution to journalArticle

He, Yantao ; Zeng, Li Fan ; Yu, Zhi Hong ; He, Rongjun ; Liu, Sijiu ; Zhang, Zhong-Yin. / Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors. In: Bioorganic and Medicinal Chemistry. 2012 ; Vol. 20, No. 6. pp. 1940-1946.
@article{2bb2711534c34601bdcab31c50c2081a,
title = "Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors",
abstract = "Protein tyrosine phosphatases (PTPs) constitute a large and structurally diverse family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. Malfunction of PTP activity has significant implications in many human diseases, and the PTP protein family provides an exciting array of validated diabetes/obesity (PTP1B), oncology (SHP2), autoimmunity (Lyp), and infectious disease (mPTPB) targets. However, despite the fact that PTPs have been garnering attention as novel therapeutic targets, they remain largely an untapped resource. The main challenges facing drug developers by the PTPs are inhibitor specificity and bioavailability. Work over the last ten years has demonstrated that it is feasible to develop potent and selective inhibitors for individual members of the PTP family by tethering together small ligands that can simultaneously occupy both the active site and unique nearby peripheral binding sites. Recent results with the bicyclic salicylic acid pharmacophores indicate that the new chemistry platform may provide a potential solution to overcome the bioavailability issue that has plagued the PTP drug discovery field for many years. Structural analysis of PTP-inhibitor complexes reveals molecular determinants important for the development of more potent and selective PTP inhibitors, thus offering hope in the medicinal chemistry of a largely unexploited protein class with a wealth of attractive drug targets.",
keywords = "Bioavailability, Combinatorial chemistry, Inhibitor specificity, Protein tyrosine phosphatases, Salicylic acid, Therapeutic target",
author = "Yantao He and Zeng, {Li Fan} and Yu, {Zhi Hong} and Rongjun He and Sijiu Liu and Zhong-Yin Zhang",
year = "2012",
month = "3",
day = "15",
doi = "10.1016/j.bmc.2011.11.004",
language = "English",
volume = "20",
pages = "1940--1946",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Bicyclic benzofuran and indole-based salicylic acids as protein tyrosine phosphatase inhibitors

AU - He, Yantao

AU - Zeng, Li Fan

AU - Yu, Zhi Hong

AU - He, Rongjun

AU - Liu, Sijiu

AU - Zhang, Zhong-Yin

PY - 2012/3/15

Y1 - 2012/3/15

N2 - Protein tyrosine phosphatases (PTPs) constitute a large and structurally diverse family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. Malfunction of PTP activity has significant implications in many human diseases, and the PTP protein family provides an exciting array of validated diabetes/obesity (PTP1B), oncology (SHP2), autoimmunity (Lyp), and infectious disease (mPTPB) targets. However, despite the fact that PTPs have been garnering attention as novel therapeutic targets, they remain largely an untapped resource. The main challenges facing drug developers by the PTPs are inhibitor specificity and bioavailability. Work over the last ten years has demonstrated that it is feasible to develop potent and selective inhibitors for individual members of the PTP family by tethering together small ligands that can simultaneously occupy both the active site and unique nearby peripheral binding sites. Recent results with the bicyclic salicylic acid pharmacophores indicate that the new chemistry platform may provide a potential solution to overcome the bioavailability issue that has plagued the PTP drug discovery field for many years. Structural analysis of PTP-inhibitor complexes reveals molecular determinants important for the development of more potent and selective PTP inhibitors, thus offering hope in the medicinal chemistry of a largely unexploited protein class with a wealth of attractive drug targets.

AB - Protein tyrosine phosphatases (PTPs) constitute a large and structurally diverse family of signaling enzymes that control the cellular levels of protein tyrosine phosphorylation. Malfunction of PTP activity has significant implications in many human diseases, and the PTP protein family provides an exciting array of validated diabetes/obesity (PTP1B), oncology (SHP2), autoimmunity (Lyp), and infectious disease (mPTPB) targets. However, despite the fact that PTPs have been garnering attention as novel therapeutic targets, they remain largely an untapped resource. The main challenges facing drug developers by the PTPs are inhibitor specificity and bioavailability. Work over the last ten years has demonstrated that it is feasible to develop potent and selective inhibitors for individual members of the PTP family by tethering together small ligands that can simultaneously occupy both the active site and unique nearby peripheral binding sites. Recent results with the bicyclic salicylic acid pharmacophores indicate that the new chemistry platform may provide a potential solution to overcome the bioavailability issue that has plagued the PTP drug discovery field for many years. Structural analysis of PTP-inhibitor complexes reveals molecular determinants important for the development of more potent and selective PTP inhibitors, thus offering hope in the medicinal chemistry of a largely unexploited protein class with a wealth of attractive drug targets.

KW - Bioavailability

KW - Combinatorial chemistry

KW - Inhibitor specificity

KW - Protein tyrosine phosphatases

KW - Salicylic acid

KW - Therapeutic target

UR - http://www.scopus.com/inward/record.url?scp=84857911995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857911995&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2011.11.004

DO - 10.1016/j.bmc.2011.11.004

M3 - Article

C2 - 22133902

AN - SCOPUS:84857911995

VL - 20

SP - 1940

EP - 1946

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 6

ER -